Search Result

Results for "

IMC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (1) c-Met/HGFR (1) CD3 (1) FGFR (1) IGF-1R (1) Interleukin Related (1) NO Synthase (1) PD-1/PD-L1 (1) PDGFR (1) Tyrosinase (2) VEGFR (1)
By Research Areas:	Cancer (9) Infection (1) Inflammation/Immunology (6) Metabolic Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9922

Olaratumab IMC-3G3; LY3012207	PDGFR	Cancer
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .

HY-P99622

Flanvotumab IMC-20D7S	Tyrosinase	Cancer
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .

HY-P99364

Icrucumab Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR	Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .

HY-P99189

Cixutumumab IMC-A12; NSC742460	IGF-1R	Cancer
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .

HY-P99375

Narnatumab IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)	Tyrosinase c-Met/HGFR	Cancer
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a K_d of 32 pM. Narnatumab can be used for the research of cancer .

HY-P991106

IMC-D11 LY-3076226 antibody	FGFR	Cancer
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990014

Danburstotug IMC-001; STI-3031	PD-1/PD-L1	Inflammation/Immunology Cancer
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .

HY-P990608

Alpitatug IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)	CD3	Inflammation/Immunology
Alpitatug (IMC 3C5) is a CHO-expressed human antibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-N10653

Altemicidin (-)-Altemicidin	Others	Cancer
Altemicidin is a monoterpene alkaloid originally isolated from S. sioyaensis with acaricidal and anticancer activities. It is acaricidal to two-spotted spider mites (T. urticae) in a greenhouse pot test at concentrations of 10 and 100 ppm. Altemicidin inhibits the growth of murine L1210 lymphocytic leukemia and IMC carcinoma cells (IC₅₀s=0.84 and 0.82 μg/mL, respectively). It is toxic to mice with an LD₅₀ value of 0.3 mg/kg.

HY-19606

Cytogenin Antibiotic MI 43-37F11	Interleukin Related NO Synthase	Metabolic Disease Inflammation/Immunology Cancer
Cytogenin (Antibiotic MI 43-37F11) is an orally active antineoplastic antibiotic. Cytogenin regulates the inflammatory cytokine, reduces the levels of iNOS, NO and IL-6 in mouse macrophages, and exhibits antidiabetic efficacy in mice. Cytogenin inhibits growth of Ehrlich ascites tumor in mouse model .

HY-121365

Forphenicinol	Bacterial	Infection
Forphenicinol is an immunomodulator and a derivative of the bacterial metabolite forphenicine. It increases the phagocytosis of yeast by peritoneal macrophages isolated from thioglycolate-stimulated mice. Forphenicinol (100 μg/animal) prevents cyclophosphamide-induced suppression of delayed-type hypersensitivity (DTH), as well as enhances DTH in response to the hapten oxazolone or sheep red blood cells in mice. It enhances the bactericidal activity of macrophages against P. aeruginosa in mice when administered at a dose of 0.5 mg/kg.2 Forphenicinol (15.6-1,000 μg/animal) increases survival in a mouse model of P. aeruginosa infection. It also inhibits tumor growth in S180 sarcoma and IMC carcinoma mouse xenograft models when administered at doses ranging from 0.05 to 5 mg/kg per day.

Cat. No.	Product Name	Target	Research Area

HY-P9922

Olaratumab IMC-3G3; LY3012207	PDGFR	Cancer
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .

HY-P99622

Flanvotumab IMC-20D7S	Tyrosinase	Cancer
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .

HY-P99364

Icrucumab Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR	Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .

HY-P99189

Cixutumumab IMC-A12; NSC742460	IGF-1R	Cancer
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .

HY-P99375

Narnatumab IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)	Tyrosinase c-Met/HGFR	Cancer
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a K_d of 32 pM. Narnatumab can be used for the research of cancer .

HY-P990621

*LY3022859 (IMC-TR1)* IMC-TR1	Inhibitory Antibodies	Inflammation/Immunology
LY3022859 (IMC-TR1) is a CHO-expressed human antibody that targets TBFbR2. LY3022859 (IMC-TR1) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 143 kDa. The isotype control for LY3022859 (IMC-TR1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991106

IMC-D11 LY-3076226 antibody	FGFR	Cancer
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990014

Danburstotug IMC-001; STI-3031	PD-1/PD-L1	Inflammation/Immunology Cancer
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .

HY-P990603

IMC-C103C RG-6290	Inhibitory Antibodies	Inflammation/Immunology
IMC-C103C is a human antibody expressed in CHO cells, targeting MAGE-A4. IMC-C103C contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for IMC-C103C can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990608

Alpitatug IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)	CD3	Inflammation/Immunology
Alpitatug (IMC 3C5) is a CHO-expressed human antibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990489

*Anti-PDGFRB/CD140b Antibody (IMC-2C5)* IMC-2C5	Inhibitory Antibodies	Inflammation/Immunology

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.